Fig. 6
Organoid-based drug screening platform enables the identification of therapeutic agents against Kras-driven LUAD. A) Schematic showing the workflow of image-based drug screening. B) Distribution of values of average area and density ratio for healthy and KP organoids. C-D) Representative images and dose–response curves for amuvatinib, midostaurin, and selumetinib on KP, and KPC organoids. E–F) Brightfield images and dose–response curves of KP and KPC mutated organoids after treatment with epigenetic drug- decitabine. IC50 is the half-maximal inhibitory concentration of the drug in each model. Data represents the mean ± standard deviation, n = 3 technical replicates. G-H) Combination treatment and synergy analysis of midostaurin with decitabine on KP and KPC organoids. The heatmaps display growth inhibition (%) across different concentration combinations. The tables below the synergy maps present the most synergistic area scores calculated using the Bliss and HSA synergy models.A synergy score between -10 and 10 indicates an additive effect, while scores above 10 suggest synergy. KRASi: KRAS inhibitor, Mido: midostaurin, Deci: decitabine